Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines.
Few data are available on the effect of a booster dose of acellular pertussis vaccine in children primed as infants with acellular vaccine. We administered acellular pertussis vaccine (ACV) at 19 months to children immunized in infancy with ACV or whole cell vaccine. Forty-one infants had been randomly assigned to receive either ACV or whole cell vaccine at 2, 4 and 6 months of age. Antibody titers to pertussis toxin and filamentous hemagglutinin were significantly higher in ACV than whole cell vaccine recipients at 7 months; at 15 months antibody to filamentous hemagglutinin (but not pertussis toxin) remained significantly higher among those receiving ACV. At 19 months all 41 children received an ACV booster. Local and systemic reactions were few and minor and were equally distributed between the two groups. All children responded to booster with significant increases in antibody; these increases tended to be greater for those having been primed with ACV. ACV booster immunization appears safe and immunogenic, regardless of the vaccine given for primary immunization.
Edwards
K M
KM
Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN.
Decker
M D
MD
Bradley
R B
RB
Taylor
J C
JC
Hager
C C
CC
D000367:Age Factors; D000907:Antibodies, Bacterial / Q000032:analysis*; D006388:Hemagglutinins / Q000276:immunology; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D007223:Infant; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology*; D010566:Virulence Factors, Bordetella / Q000276:immunology*
D000907:Antibodies, Bacterial; D006388:Hemagglutinins; D010567:Pertussis Vaccine; D010566:Virulence Factors, Bordetella; D037342:Pertussis Toxin